TY - JOUR T1 - Recent updates from the <em>BNF</em> JF - Drug and Therapeutics Bulletin JO - Drug Ther Bull SP - 152 LP - 153 DO - 10.1136/dtb.2019.000067 VL - 57 IS - 10 A2 - , Y1 - 2019/10/01 UR - http://dtb.bmj.com/content/57/10/152.abstract N2 - The BNF is jointly published by the Royal Pharmaceutical Society and BMJ. BNF is published in print twice a year and interim updates are issued and published monthly in the digital versions. The following summary provides a brief description of some of the key changes that have been made to BNF content since the last print edition (BNF 77) was published.Ertugliflozin (Steglatro)A new addition to the sodium-glucose co-transporter 2 (SGLT2) inhibitors family, for the treatment of type 2 diabetes mellitus in adults, either as monotherapy (if metformin is deemed inappropriate due to intolerance or contra-indications) or in combination with insulin or other antidiabetic drugs if existing treatment fails to achieve adequate glycaemic control.Hypoglycaemia is a side effect of ertugliflozin when used in combination with insulin or a sulfonylurea. Therefore, concomitant insulin or drugs that stimulate insulin secretion may require dose reduction.A drug safety update from the Medicines and Healthcare products Regulatory Agency (MHRA)/Commission on Human Medicines (CHM) reports Fournier’s gangrene (necrotising fasciitis of the genitalia or perineum), a rare but serious and potentially life-threatening infection with SGLT2 inhibitors. For further information please visit: https://www.gov.uk/drug-safety-update Insulin glargine with lixisenatide (Suliqua)A novel medicinal combination containing a long-acting recombinant human insulin analogue and a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist … ER -